Skip to content
DataLookout
Menu

NCT07913672

A Study of LBP-MARCO and Ruxolitinib in People With Graft-Versus-Host Disease (GVHD)

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

incidence and severity of SAEs
Timeframe: up to 100 days

Secondary (1)

Microbiota engraftment/PK

Arms and interventions

Consortia AExperimental

Participants in Cohort 1 will receive LBP-MARCO with the same combination of 7 specific types of bacteria.

Consortia BExperimental

If the bacteria do not grow or produce enough metabolites, the next group of participants (Cohort 2) will get LBP-MARCO with a different combination of bacteria.

Consortia CExperimental

If that combination does not grow in participants' guts, the next group of participants (Cohort 3) will get LBP-MARCO with a different combination of the bacteria.

Drugs: Ruxolitinib

Other: LBP- MARCO

Sites

7 sites in 1 country